study after study has shown that when clinical trials involve entities with a financial interest in the outcome , as the parker institute for cancer immunotherapy and penn have in this one , the reported outcomes are more likely to be favorable than when the trial is sponsored by , say , the national institutes of health . in studies where the sponsor has a profit motive , scientists are also less likely to adhere to best practices , research has shown . " if you really believe in a [ bio ] technology and it is not completely clear whether a side effect is the fault of the disease or the technology , your bias could influence how you interpret that , " said atkins .